Skip to main content
Clinical Trials/NCT05181488
NCT05181488
Active, not recruiting
Not Applicable

A Prospective, Phase II Study Evaluating the Efficacy of Intraoperative Radiotherapy After Neoadjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer

Yona Cho1 site in 1 country80 target enrollmentApril 2, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Resectable Pancreatic Cancer
Sponsor
Yona Cho
Enrollment
80
Locations
1
Primary Endpoint
3-year local recurrence rate
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

This phase II study is designed to investigate the efficacy of intraoperative radiotherapy after neoadjuvant chemotherapy in patients with resectable pancreatic cancer. The purpose of the study is to show the local recurrence rate after neoadjuvant chemotherapy and IORT is superior to that of surgical resection alone from the historical control. A total of 80 patients will be enrolled, and these patients will receive IORT of 10 Gy at 5 millimeter depth of the tumor bed, following neoadjuvant chemotherapy.

Registry
clinicaltrials.gov
Start Date
April 2, 2020
End Date
April 1, 2026
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Yona Cho
Responsible Party
Sponsor Investigator
Principal Investigator

Yona Cho

Assistant Professor

Gangnam Severance Hospital

Eligibility Criteria

Inclusion Criteria

  • Histologically diagnosed with adenocarcinoma of the pancreas or clinically diagnosed with imaging examinations or tumor markers
  • 20 years or older
  • Performance status 0-2 based on Eastern Cooperative Oncology Group (ECOG)
  • Patients with surgically resectable or borderline resectable and advanced pancreatic cancer that can be resected after neoadjuvant chemotherapy
  • Patients who voluntarily decided to participate in this clinical study and signed a written informed consent

Exclusion Criteria

  • History of previous abdominal irradiation.
  • When the treatment area is not included in the appropriate radiation field according to the judgment of the radiation oncologist or Durgeon
  • Distant metastasis
  • Other systemic conditions that, under the judgment of the attending physician, would be difficult to undergo surgery or radiiotherapy

Outcomes

Primary Outcomes

3-year local recurrence rate

Time Frame: 3 year after intraoperative radiotherapy

A local recurrence is defined as reappearance of cancer in the ipsilateral preserved breast or chest wall. The 3-year local recurrence rate is calculated using the Kaplan-Meier method.

Secondary Outcomes

  • disease free survival(1 year and 2 year after intraoperative radiotherapy.)
  • Overall survival(1 year and 2 year after intraoperative radiotherapy.)
  • post-operative complication(3 year after intraoperative radiotherapy)

Study Sites (1)

Loading locations...

Similar Trials